Genprex

Genprex sees newly licensed diabetes gene therapy as an ‘opportunity we couldn’t pass up’

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based biotech has signed a licensing agreement with the University of Pittsburgh for a diabetes gene therapy that could have the potential to treat Type 1 and Type 2 diabetes.